Sponsors (25)
The bill trades stronger public and congressional transparency and better GAO/CBO-informed oversight of drug-manufacturer agreements—which can expose costs, competition issues, and enable corrective action—for the risk that legal pushback, privacy/commercial exposure, compressed deadlines, and added agency and litigation costs will limit disclosures and strain federal resources.
Patients (including those with chronic conditions), uninsured people, and Medicare/Medicaid beneficiaries gain public transparency into drug-manufacturer agreements and analyses of who benefits and how much, enabling scrutiny that can inform policies to improve access and lower out-of-pocket costs.
Congressional committees, oversight bodies, and the public get stronger accountability because HHS must publish justifications for redactions and provide an inventory of released/withheld documents, improving scrutiny of executive agreements with industry.
Policymakers and taxpayers benefit from a joint GAO/CBO analysis of budgetary, beneficiary, and market impacts (within 90 days), giving rigorous information to detect cost drivers, target corrective actions, and address anti-competitive practices.
Patients and the public may get limited benefit if drug manufacturers refuse to provide confidential pricing data or invoke foreign/settlement laws, allowing companies to block or delay disclosures.
Federal agencies and employees (HHS, GAO, CBO) face significant resource and timeline strain from short statutory deadlines (30/15/90 days), risking rushed or incomplete disclosures and diverting staff from other work.
Taxpayers could face higher legal and administrative costs if reports and disclosures provoke public disputes or litigation over withholdings, and implementation timelines are extended by legal challenges.
Based on analysis of 4 sections of legislative text.
Requires HHS to publish federal agreements with drug manufacturers (post‑Jan 20, 2025) in a central searchable format, limits redactions, and mandates congressional and CBO/GAO reports.
Official title: To require the Department of Health and Human Services to release documents, communications, and other information relating to most favored nation pricing agreements and other private or confidential drug pricing deals struck with manufacturers, and for other purposes.
Introduced July 15, 2026 by Judy Chu · Last progress July 15, 2026
Requires the HHS Secretary to publish, in a centralized searchable and downloadable format, federal agreements with named drug manufacturers made on or after January 20, 2025, and to disclose whether manufacturers provided confidential pricing information. It limits redactions to narrowly defined legal protections and requires written justification for any redaction. The bill also requires a near-term report to Congress listing released and withheld materials and a joint CBO/GAO analysis of budgetary, market, and beneficiary impacts within set deadlines.